EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis

Fan Huang, Dingyuan Hu iD, Huaying Fan, Binyi Hu, Yian Liu, Wenliang Dong, Xiangxing Liu, Yanting Li, Diqin Yan iD, Rui Ding, Suping Niu, Liming Chen und 2 weitere

Clinical Pharmacology & Therapeutics · 2025-03 · 117 (3) · 659-669

DOI: 10.1002/cpt.3538 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 23.12.2024. Verfasst von Fan Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Institution, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Vitiligo, Janus Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although several case reports and small clinical trials have reported promising outcomes with Janus kinase (JAK) inhibitors for vitiligo, high‐quality evidence and guidelines are lacking. We evaluated the efficacy and safety of JAK inhibitors for the treatment of vitiligo using a meta‐analysis of randomized controlled trials (RCTs). We searched the PubMed, Embase, and Cochrane Library databases up to August 2023, with additional studies from ClinicalTrials.gov and company websites. We assessed outcomes, including percentage improvement in total vitiligo area score index (TVASI) and facial vitiligo area score index (FVASI); the proportion of patients achieving 50% improvement in TVASI (TVASI50) and 50% and 75% improvement in FVASI (FVASI50 and FVASI75); the risk of treatment‐emergent adverse events (TEAEs), serious adverse events (SAEs), infections, and skin‐related adverse events (AEs). Five studies with 1,550 participants were included. JAK inhibitors were associated with a higher proportion of TVASI50 (relative risk [RR] 2.67, 95% confidence interval [CI] 1.24–5.78) and FVASI75 (RR 3.97, 95%CI 2.62–6.02) responders than placebo. JAK inhibitors significantly increased the risk of skin‐related AEs (RR 1.96, 95% CI 1.29–2.98) compared with placebo. However, the risk of TEAEs, SAEs, and infections was not significantly different between the JAK inhibitor and placebo groups. Subgroup analysis showed that JAK1 and JAK1/2 inhibitors were more effective than JAK3 inhibitors. However, there was insufficient evidence to suggest that the route of administration affects the efficacy and safety of JAK inhibitors in vitiligo. These findings indicate that JAK inhibitors are effective in repigmentation and well tolerated in patients with vitiligo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoJanus Kinase InhibitorsHumansRandomized Controlled Trials as TopicTreatment Outcome

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
  • Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
  • Department of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.

ORCID-Profile: Dingyuan Hu, Diqin Yan, Xiaoyan Nie, Yi Fang

Zitieren

APA

Huang, F., Hu, D., Fan, H., Hu, B., Liu, Y., Dong, W., Liu, X., Li, Y., Yan, D., Ding, R., Niu, S., Chen, L., Nie, X., & Fang, Y. (2025). Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis. Clinical Pharmacology & Therapeutics, 117(3), 659-669. https://doi.org/10.1002/cpt.3538

Vancouver

Huang F, Hu D, Fan H, Hu B, Liu Y, Dong W, et al. Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis. Clinical Pharmacology & Therapeutics. 2025;117(3):659-669. doi:10.1002/cpt.3538

BibTeX
@article{Huang2025,
  author = {Huang, Fan and Hu, Dingyuan and Fan, Huaying and Hu, Binyi and Liu, Yian and Dong, Wenliang and Liu, Xiangxing and Li, Yanting and Yan, Diqin and Ding, Rui and Niu, Suping and Chen, Liming and Nie, Xiaoyan and Fang, Yi},
  title = {Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {3},
  pages = {659--669},
  doi = {10.1002/cpt.3538}
}
Kostenlos starten →